Anand Krishnan V Iyer
Overview
Explore the profile of Anand Krishnan V Iyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
4658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaushik V, Kulkarni Y, Felix K, Azad N, Iyer A, Yakisich J
World J Stem Cells
. 2021 Aug;
13(7):934-943.
PMID: 34367485
The classical cancer stem cell (CSCs) theory proposed the existence of a rare but constant subpopulation of CSCs. In this model cancer cells are organized hierarchically and are responsible for...
2.
Klionsky D, Abdel-Aziz A, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al.
Autophagy
. 2021 Feb;
17(1):1-382.
PMID: 33634751
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our...
3.
Pavuluri N, Aparasu R, Boje K, Danielson J, El-Ibiary S, Iyer A, et al.
Am J Pharm Educ
. 2019 Sep;
83(6):6959.
PMID: 31507290
Members from Cohort 13 of the Academic Leadership Fellows Program (ALFP) 2016-2017 were challenged to present a debate on the topic: "In Turbulent Times, Pharmacy Education Leaders Must Take Aggressive...
4.
Kulkarni Y, Dutta S, Iyer A, Wright C, Ramesh V, Kaushik V, et al.
Proteomics Clin Appl
. 2017 Dec;
12(3):e1700086.
PMID: 29283216
Purpose: Poor molecular characterization of idiopathic pulmonary fibrosis (IPF) has led to insufficient understanding of the pathogenesis of the disease, resulting in lack of effective therapies and poor prognosis. Particularly,...
5.
Yakisich J, Kulkarni Y, Azad N, Iyer A
Stem Cells Int
. 2017 Dec;
2017:5987015.
PMID: 29201061
The presence of highly resistant cancer cells and the toxicity to normal cells are key factors that limit chemotherapy. Here, we used two models of highly resistant lung cancer cells:...
6.
Guishard A, Yakisich J, Azad N, Iyer A
J Clin Neurosci
. 2017 Oct;
47:28-42.
PMID: 29066236
Despite the vast amounts of information gathered about gliomas, the overall survival of glioma patients has not improved in the last four decades. This could partially be due to an...
7.
Kulkarni Y, Yakisich J, Azad N, Venkatadri R, Kaushik V, ODoherty G, et al.
Tumour Biol
. 2017 Jun;
39(6):1010428317705331.
PMID: 28618929
While there are targeted treatments for triple positive breast cancers, lack of specific biomarkers for triple-negative breast cancers (TNBC) has hindered the development of therapies for this subset of cancers....
8.
Venkatadri R, Iyer A, Kaushik V, Azad N
Pharmacol Rep
. 2017 Jun;
69(4):788-797.
PMID: 28605700
Background: Resveratrol is a dietary compound that has been widely reported for its anticancer activities. However, successful extrapolation of its effects to pre-clinical studies is met with limited success due...
9.
Wright C, Iyer A, Kaushik V, Azad N
J Cell Biochem
. 2017 Apr;
118(11):3834-3845.
PMID: 28387458
Prostate cancer (PCa) is one of the leading causes of cancer-related deaths in men worldwide. Fatty acid synthase (FASN) is reported to be overexpressed in several cancers including PCa, and...
10.
Yakisich J, Azad N, Kaushik V, ODoherty G, Iyer A
Tumour Biol
. 2017 Mar;
39(3):1010428317694310.
PMID: 28351327
Multiple factors including tumor heterogeneity and intrinsic or acquired resistance have been associated with drug resistance in lung cancer. Increased stemness and the plasticity of cancer cells have been identified...